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Panoptic Overview of Triple-Negative 
Breast Cancer in Nigeria: Current 
Challenges and Promising Global 
Initiatives
TRIPLE-NEGATIVE BREAST CANCER: A 
CONFLUENCE OF COMPLEX CHALLENGES
Triple-negative breast cancer (TNBC) accounts 
for 20% (approximately 0.17 million) of breast 
cancer (BC) cases worldwide but remains the 
most deadly subgroup of BCs.1 Defined by the 
absence of therapeutically targetable estrogen 
receptor (ER), progesterone receptor, and human 
epidermal growth factor receptor 2 overexpres-
sion, TNBCs often present with more aggres-
sive clinicopathologic features (eg, basal-like 
phenotype, higher grade and stage, greater 
proliferation) than luminal tumors.1,2 Currently, 
no targeted therapies are approved for TNBC; 
thus, surgery, anthracycline- and taxane-based 
chemotherapy, and radiation therapy are the pri-
mary treatment options for patients with TNBC. 
Despite these treatments, TNBCs run a high 
risk of progression, especially within the first 5 
years after diagnosis.3 Rampant interpatient and 
intratumor heterogeneity render management of 
this disease complex and warrant deeper dis-
section of the molecular landscape of TNBC.4 
Nongenetic factors such as health care facilities, 
resource constraints in patients’ countries, and 
lifestyle, epidemiologic, and cultural factors all 
collude and contribute to the burden that TNBC 
imposes on patients and families, as the disease 
takes away years from life and life from years. 
Thus, enhancing our understanding of tumor 
Purpose Triple-negative breast cancer (TNBC) is the most deadly form of breast cancer (BC) today. 
TNBC treatment is fraught with challenges because of the extensive interpatient heterogeneity in 
clinical behavior and scarcity of stratifying biomarkers and actionable targets. Women of African 
ancestry face a disproportionate burden resulting from this disease, which affects them earlier 
and more aggressively and has a higher propensity to spread and resist conventional treatments. 
A much higher proportion of Nigerian patients with BC have TNBC compared with patients with BC 
in the United States and Europe.
Methods This article spotlights Nigeria as an example of a nation wherein genetic and nongenetic 
spheres of influence intersect to affect the prevalence of this disease, the scale of its challenge, 
and its toll.
Results Studies have illuminated the inherently different tumor biology of Nigerian TNBCs, which 
show distinct genetic variants and gene expression patterns compared with European or Europe-
an-American TNBCs. Parallels are apparent between TNBC phenotypes among African Americans 
and Nigerians, implicating the common thread of shared genetic ancestry between these popula-
tions. Reproductive, lifestyle, socioeconomic, and cultural factors also shape TNBC outcomes in 
Nigeria, as do resource constraints in Nigerian health care and research sectors.
Conclusion Increasing our understanding of how these factors contribute to poorer outcomes 
among Nigerian women may uncover valuable insights and strategies in alleviating the TNBC 
burden in many countries of the world and help reduce the racial disparity in BC-related outcomes 
here in the United States. Importantly, this review also highlights collaborative global and local 
initiatives that converge expertise and resources to advance research on effective management 
of TNBC in diverse populations.
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Table 1. Potential Biomarkers Underlying Nigerian TNBC
Genetic Variant
Detection 
Technique Biomarker Description TNBC Risk Association Potential Therapeutic Agents
Ancestry 
informative 
markers
Genome-wide 
admixture 
mapping
SNPs associated with 
European and African 
ancestry
ER-positive/PR-positive and early-stage 
BC associated with European AIMs13
TERT 
rs10069690 
SNP in 5p15
Genome-wide 
association 
study
Low-penetrance genetic 
variant; higher frequency 
of the allele in women of 
African ancestry
Strongly associated with ER-negative/
PR-negative BC and TNBC13
BRCA1 mutation Whole-genome 
sequence 
analysis
Tumor suppressor gene 
involved in DNA damage 
repair; associated with 
poor prognosis in BC and 
increased sensitivity to 
DNA damage agents
Associated with a 50% increased 
risk for TNBC; prevalence is only 
approximately 1.4% in AAs but 
approximately 7% among Nigerian 
patients with BC15
Platinum-based DNA damage 
agents (eg, cisplatin, 
carboplatin), PARP inhibitors
Mutant p53 IHC Tumor suppressor gene 
involved in DNA damage 
repair; associated with 
poor survival, metastasis, 
and chemotherapy 
resistance in BC
Higher expression in Nigerian BC 
cases compared with grade-
matched BC specimens from United 
Kingdom; positively correlated 
with ER-negative/PR-negative 
BC, TNBC, basal-like phenotype, 
premenopausal status, younger 
age at diagnosis, larger tumor size, 
and LVI; more frequent in Nigerian 
patients than in UK patients17
p53 induction of massive 
apoptosis (PRIMA-1), WEE1 
or CHK1 inhibition, and p53 
mutant–specific inhibitors
Aurora A IHC Tumor suppressor and 
regulator of stem-cell 
renewal
Overexpression associated with ER-
negative/PR-negative status, TNBC, 
basal-like BC; expression correlated 
with downregulation of E-cadherin 
and upregulation of CK5/6 and Ki67 
among Nigerian patients with BC18
Aurora kinase inhibitors
Ku 70/80 IHC NHEJ regulator; associated 
with higher grade, LVI, 
ER-negative status, and 
basal-like phenotype 
among patients with BC
Expression positively correlated 
with TNBC and basal-like 
phenotype, metastatic disease, and 
downregulation of BRCA1 and p53; 
expression prognostic in Nigerian 
patients19
Ki67 IHC Cell proliferation biomarker; 
expressed higher in 
AA compared with EA 
patients with BC
Higher expression in Nigerian patients 
with BC compared with grade-
matched UK patients with BC; 
expression positively correlated 
with TNBC status and/or basal-like 
tumor biology, downregulation of 
E-cadherin, BRCA1 mutation, and 
upregulation of p53, CK5/6, and 
CK1620
PARP1 IHC Repairs DNA damage 
(ie, single-strand DNA 
breaks) through poly-ADP 
ribosylation to promote 
cell survival
Expression positively correlated with 
ER-negative/PR-negative and TNBC 
status, basal-like BC, higher grade, 
CK5/6 and CK14 expression, p53, 
EGFR, Ki67, and PI3KCA expression; 
poor prognosis biomarker in Nigerian 
patients with BC21
PARP1 inhibitors
PIASγ IHC Inhibitor of STAT signaling 
pathway; E3 SUMO 
protein ligase; implicated 
in BRCA1 deficiency and 
TNBC status
Expression positively correlated with 
high grade, expression of basal-like 
biomarkers, ER-negative/PR-negative 
status, TNBC, basal-like phenotype; 
poor prognosis biomarker in Nigerian 
patients with BC22
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biology and modifiable factors that influence 
clinical outcomes, identifying better biomarkers 
for patient stratification, and developing newer, 
more effective targeted therapies are critical for 
improving TNBC management globally.
Several studies have suggested that biogeo-
graphic ancestry might be a key driver of 
aggressive BC. Women of African ancestry are 
disproportionately affected by TNBC, with poorer 
clinical outcomes compared with patients with 
BC of other ethnicities. In the United States, Afri-
can American (AA) women are two to three times 
more likely to be diagnosed with TNBC com-
pared with European Americans (EAs).5 Among 
patients with TNBC, AAs are more likely to expe-
rience rapid disease progression and shorter 
survival times than EAs. Furthermore, TNBC is 
significantly more prevalent and presents with 
higher grade and earlier onset among West Afri-
can (WA) women compared with AA women.6 
Thus, clearer understanding of the interplay 
between genetic and nongenetic causes of 
higher TNBC prevalence in WA women, who 
share a common ancestry with AAs because of 
the trans-Atlantic colonial slave trade, may allow 
us to design better strategies (health care guide-
lines and policies, preventative measures, stra-
tegic investment in infrastructure) to ameliorate 
global TNBC burden and racial disparity in BC 
outcomes in the United States. Essentially, this 
review aims to dissect the complex landscape 
of Nigerian TNBC to understand drivers of the 
disproportionate burden of TNBC in WA women 
and racial disparity in outcomes in the United 
States and to highlight concerted global and 
local initiatives and collaborative interventions 
across multiple stakeholders that aim to drive 
sustainable change and reduce the devastating 
footprint of this disease.
RETURNING TO OUR ROOTS: DIGGING DEEP INTO 
THE LANDSCAPE OF TNBC IN NIGERIA TO BETTER 
MANAGE TNBC WORLDWIDE
“The roots of education are bitter, but the fruit is 
sweet.” —Aristotle
Ancestry genotyping studies show that the 
AA population predominantly harbors West 
or West-Central African ancestry, presumably 
because of the colonial slave trade.7 Mortal-
ity rates have been reported to be much lower 
among East African compared with WA patients 
with BC, suggesting that WA ancestry may 
explain, at least in part, poorer clinical outcomes 
between AA and EA patients.8 Nigeria, the larg-
est and most populous developing country in 
Africa, exemplifies the current dismal state of BC 
in WA. There are more than 27,000 new cases of 
BC annually in Nigeria; roughly 70% to 80% of 
these patients present with locally advanced or 
metastatic BC, and nine of 10 of these women 
die within the first 5 years.9 The mean age at 
presentation for Nigerian patients with BC is 
approximately 43 years, with 74% identified 
as premenopausal and 12% younger than age 
30 years.10 A large percentage of Nigerian BC 
cases are often classified as TNBC, although it 
has been suggested that many of these cases 
are false negatives, resulting from suboptimal 
tissue fixation and pathology practices.11,12 Over 
the next few sections, we discuss contributions 
of genetic and nongenetic factors to the etiology 
and prognosis of TNBC in Nigeria and explore 
how this knowledge could inform clinicians 
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Table 1. Potential Biomarkers Underlying Nigerian TNBC (Continued)
Genetic Variant
Detection 
Technique Biomarker Description TNBC Risk Association Potential Therapeutic Agents
ALDH1 IHC Cancer stem- and 
progenitor-cell marker
Higher expression in Ghanian patients 
with BC; expression associated with 
TNBC23
ALDH1 inhibitors
EZH2 IHC Oncogene involved in 
transcriptional repression; 
strongly association with 
ER-negative/PR-negative 
and metastatic BC and 
poorer clinical outcomes
Overexpression positively correlated 
with high tumor grade and basal-
like phenotype; cytoplasmic EZH2 
expression associated with TNBC 
among Ghanian patients with BC24
EZH2 and HMT inhibitors
Abbreviations: AA, African American; AIM, ancestry informative marker; BC, breast cancer; EA, European American; EGFR, epidermal growth factor receptor; ER, 
estrogen receptor; HMT, histone methyltransferase; IHC, immunohistochemistry; LVI, lymphovascular invasion; NHEJ, nonhomologous end joining; PARP, poly (ADP-ri-
bose) polymerase; PI3K, phosphatidylinositol 3-kinase; PR, progesterone receptor; SNP, single-nucleotide polymorphism; STAT, signal transducer and activator of 
transcription; TNBC, triple-negative breast cancer.
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about strategies to more effectively overcome 
the disease.
WE CANNOT HELP WHAT WE ARE BORN WITH: 
GENETIC RISK FACTORS IN NIGERIAN TNBC
“We can’t choose where we come from, but we 
can choose where we go from there.” —Steven 
Chbosky
The stark disparity in TNBC prevalence and 
mortality between WA women and women of 
other ancestral backgrounds has spurred efforts 
to elucidate its genetic basis, as summarized 
in Table 1. Studies have identified an associa-
tion of African ancestry as well as genetic vari-
ants, more prevalent among women of African 
descent, with increased risk for more aggressive 
BC phenotypes and advanced stage.13,14 Muta-
tions in tumor suppressor genes such as BRCA1 
have also been implicated in the higher TNBC 
incidence rate in Nigeria.15,16 Furthermore, stud-
ies have uncovered multiple biomarkers that 
are generally overexpressed in Nigerian and WA 
patients with BC and are associated with TNBC 
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TNBC-related needs and resources available in Nigeria, initiate research projects 
for understanding global health disparities in TNBC, and improve TNBC clinical
management in women of African ancestry
available resources (eg, TNBC specimens from native African patients, 
deidentified patient data, local expertise) to facilitate sharing as part of joint 
projects
TNBC-related research and output of high-quality publications, training of
exchange students
questions pertaining to TNBC biology and clinical management
creative and cost-effective technologies that can improve outcomes
for patients with TNBC
researchers through exchange of students and fellows to receive training in 
advanced disciplines such histopathology, biobanking, molecular biology, 
biostatistics, bioinformatics 
ADVOCATE
TNBC burden through new cost-effective assays, easy to implement
in the clinic, for patients with TNBC  of African ancestry
for global attention to unique TNBC biology in women of African ancestry, for 
better evidence-based guidelines to promote early detection and better
managementof TNBC, and for improvement of clinical research infrastructure in Nigeria
•  Improved stratification of patients with TNBC based on biomarkers relevant to patients of
   African ancestry
•  Improved understanding of etiology and pathobiology of TNBC in women of African ancestry
•  Better training of the next generation of Nigerian BC researchers
•  Attract investment in research infrastructure in Nigeria
•  Reduce TNBC burden in Nigeria
CONSOLIDATE
ACCELERATE
INVESTIGATE
INNOVATE
EDUCATE
EVALUATE
ALLEVIATE
ANTICIPATED OUTCOMES
Fig 1. International 
Consortium for Advancing 
Research on Triple-Negative 
Breast Cancer (TNBC) stra-
tegic action plan for Nigeria. 
BC, breast cancer.
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status and aggressive clinicopathologic char-
acteristics (Table 1).17-24 However, additional 
research is necessary to uncover selectively 
targetable inherent tumor biologic characteris-
tics in Nigerian women to improve their disease 
outcomes. In the United States, the AA popu-
lation is highly admixed and typically harbors 
14% to 21% European ancestry and approxi-
mately 1% to 3% Native American ancestry.25 
Thus, ancestry genotyping, which has hitherto 
received scant consideration, has to be more 
firmly embedded in biomarker and drug discov-
ery and development studies and clinical trial 
designs so that the personal can be more fully 
reinstated in personalized medicine for TNBC.
NATURE VERSUS NURTURE: WHAT WE KNOW 
AND NEED TO KNOW ABOUT NONGENETIC RISK 
FACTORS FOR TNBC IN NIGERIA
“You inherit your environment as much as your 
genes.” —Johnny Rich
Studies are increasingly showing that behavioral 
and social factors profoundly influence disease 
risk, and TNBC is no exception. Because these 
are modifiable via appropriate interventions, their 
due consideration via a life course approach 
could affect TNBC diagnoses, prevalence rates, 
management strategies, and outcomes in Nige-
ria.
Epidemiologic Risk Factors
Reproductive factors. A positive association 
between higher parity and increased likelihood 
of developing TNBC and a negative associa-
tion between breastfeeding duration and risk 
of developing TNBC have been detected in AA 
women.26,27 Furthermore, one study reported 
that the use of oral hormonal contraceptives is 
associated with a 2.9 times greater risk of TNBC 
in women age between 45 and 64 years.28 Thus, 
these associations warrant further study in the 
Nigerian population.
Anthropometric factors. Obesity has been linked 
to increased risk for developing TNBC in women 
of all ethnic backgrounds.29 Obesity is increas-
ing in Nigeria because of increased consump-
tion of calorie-dense foods.30 A high hip-to-waist 
ratio, more prevalent among women of African 
descent, has been linked to increased risk for 
developing TNBC or ER-negative/progester-
one receptor–negative BC in women of African 
descent.27 Furthermore, a study conducted in 
Nigeria reported that height is significantly linked 
to increased risk for developing BC; thus, it may 
be interesting to investigate if height is associ-
ated with increased risk of TNBC in Nigeria.31
Lifestyle. Diet and nutrition may play a crit-
ical role, according to one study, which found 
that there is an inverse association between a 
diet high in fruits and vegetables and risk of 
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Table 2. Comparison of Breast Clinicopathologic Variables Between Lymph Node–
Matched Patients With BC in Nigeria and the United Kingdom
Characteristic
No. (%)
P*
United 
Kingdom† Nigeria‡
Age, years < .001
≤ 50 108 (35.1) 187 (60.7)
> 50 200 (64.9) 121 (39.3)
Menopausal status < .001
Pre 128 (41.6) 208 (67.5)
Post 180 (58.4) 100 (32.5)
Tumor grade < .001
1 28 (9.1) 8 (2.6)
2 98 (31.8) 196 (63.6)
3 182 (59.1) 104 (33.8)
Tumor size, cm < .001
≤ 2 118 (38.3) 27 (8.8)
> 2 190 (61.7) 281 (91.2)
Tumor histologic type < .001
Ductal/NST 199 (64.6) 268 (87.0)
Tubular mixed 44 (14.3) 17 (5.5)
Tubular 9 (2.9) 4 (1.3)
Lobular 22 (7.1) 4 (1.3)
Mucinous 0 (0.0) 5 (1.6)
Atypical medullary 5 (1.6) 5 (1.6)
Mixed NST 5 (1.6) 3 (1.0)
Tubulolobular 2 (0.7) 1 (0.3)
Typical medullary 0 (0.0) 1 (0.3)
Lobular mixed 13 (4.2) 0 (0.0)
Other 9 (2.9) 0 (0.0)
Vascular invasion < .001
Negative 116 (37.7) 76 (24.7)
Positive 192 (62.3) 232 (75.3)
Abbreviations: BC, breast cancer; NST, no special type.
*P values were calculated using the χ2 test.
†British cohort: 308 formalin-fixed, paraffin-embedded (FFPE) specimens from patients with BC 
presenting between 1986 and 1993 from the Nottingham-Tenovus Primary Breast Carcinoma 
Series.
‡Nigerian cohort: 308 FFPE specimens from patients with BC presenting from January 2002 to 
December 2008 at Olabisi University Teaching Hospital in Sagamu and Histopathology Specialist 
Laboratory Hospital in Idi-Araba, Lagos, Nigeria.
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developing ER-negative BC.32-34 Alcohol con-
sumption, smoking, and physical inactivity have 
all been linked to increased BC risk in Nigeria; 
thus, it may be worthwhile to investigate their 
effects on TNBC risk in Nigeria.35-37
Socioeconomic status. Irrespective of ancestral 
background, living in poor socioeconomic condi-
tions can increase a woman’s chances of being 
diagnosed with TNBC over other BC subtypes.38 
Nigeria ranks among the poorest nations in the 
world, with a population of more than 150 million 
but a gross domestic product of only US$2,000 
per capita annually.39 A study conducted in a 
Nigerian tertiary hospital found that almost 45% 
of the patients declined treatments in the mid-
dle of their chemotherapy regimens because of 
financial instability.39 Thus, the poor, marginal-
ized, and rural women of the country bear the 
most acute brunt of the burden of TNBC.
Health literacy and education. A clinical study 
conducted at the University College Hospital 
in Ibadan, Nigeria, found that approximately 
85% of Nigerian patients with BC presented 
at an advanced stage.40 Lack of knowledge of 
BC signs and symptoms are serious barriers to 
Nigerian patients receiving timely and adequate 
treatment. Although some studies report approx-
imately 80% to 92% of Nigerian women are 
aware of mammography screening, only 3% to 
10% are reported to have actually undergone the 
screening.41 Studies have revealed that Nigerian 
women with a higher level of education exhibit 
more knowledge about breast self-examination 
(BSE), tend to believe that early BC detection 
leads to better survival rates, and are more likely 
to practice BSE compared with those with a lower 
level of education.42-44 Studies have also revealed 
that most Nigerian health care providers lack 
sufficient knowledge of BC risk factors and the 
procedure for BSE.4,5 Also, single marital sta-
tus, premenopausal status, fear of discovering a 
lump, and residing in rural or remote areas have 
been associated with delay in seeking medical 
attention in Nigeria.41,45-49 A majority of Nigerian 
women obtain their BC information from televi-
sion (31%), clinics (31%), and health profes-
sionals as well as from their elders, friends, and 
neighbors among rural women according to one 
study; thus, disparities in socioeconomic sta-
tus may underlie differences in awareness and 
stage at presentation between semiurban and 
rural Nigerian communities.48,50-52 These studies 
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Table 3. Comparison of BC Biomarker Status Between Lymph Node–Matched Patients 
With BC in Nigeria and the United Kingdom
Biomarker
No. (%)
P*
United 
Kingdom† Nigeria‡
BRCA1 < .001
Negative 29 (11.0) 194 (81.5)
Positive 235 (89.0) 44 (18.5)
CK5/8 < .001
Negative 265 (86.9) 166 (64.3)
Positive 40 (13.1) 92 (35.7)
CK7/8 < .001
Negative 21 (6.9) 263 (91.0)
Positive 285 (93.1) 26 (9.0)
CK14 < .001
Negative 274 (91.3) 132 (58.9)
Positive 26 (8.7) 92 (41.1)
CK18 < .001
Negative 63 (21.7) 242 (85.5)
Positive 227 (78.3) 41 (14.5)
E-cadherin < .001
Negative 109 (35.6) 160 (70.8)
Positive 197 (64.4) 66 (29.2)
ER < .001
Negative 82 (27.0) 215 (78.5)
Positive 222 (73.0) 59 (21.5)
EGFR < .001
Negative 228 (82.3) 157 (66.8)
Positive 49 (17.7) 78 (33.2)
KI67 .02
Negative 66 (25.7) 46 (17.4)
Positive 191 (74.3) 218 (82.6)
MDM2 < .001
Negative 1 (1.1) 205 (82.0)
Positive 87 (98.9) 45 (18.0)
P-cadherin .27
Negative 140 (51.3) 124 (46.6)
Positive 133 (48.7) 142 (53.4)
PR < .001
Negative 125 (40.7) 160 (72.4)
Positive 182 (59.3) 61 (27.6)
p21 < .001
Negative 105 (51.2) 157 (71.7)
Positive 100 (48.8) 62 (28.3)
p27 .005
Negative 72 (41.6) 119 (56.1)
Positive 101 (58.4) 93 (43.9)
(Continued on following page)
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highlight a need for continuing medical and 
health education programs to improve aware-
ness among the Nigerian adult population and 
health care professionals of early detection to 
improve outcomes. Several nonprofit organiza-
tions or nongovernmental societies and commu-
nity outreach programs have been established in 
Nigeria to improve BC awareness to eventually 
reduce societal, financial, emotional, and health 
burdens resulting from TNBC.
Cultural Norms and Beliefs
Cultural traditions and spiritual beliefs in Nige-
ria can influence a patient’s decision to seek 
timely medical treatment. Some Nigerian women 
believe that unless the swelling or lump in the 
breast is painful, it is unlikely to be malignant, and 
they do not need medical attention.53 Another 
study found that 17.5% of Nigerian patients 
with BC initially consulted with traditional heal-
ers for treatment, which was associated with a 
more than 3-month delay until presentation.54 
Also, in some African cultures, people believe 
that BC is caused by social misconduct, such 
as oral or nipple contact, or a woman wearing 
unclean garments.55 Fear of being divorced by 
her husband or of being ostracized by the com-
munity, fear of disfigurement by surgery, fear of 
pain or embarrassment during medical exam-
inations (especially if the medical practitioner is 
of the opposite sex), fear of ineffective treatment, 
lack of confidence in physicians, belief that sur-
gery accelerates metastasis, fear of death, and 
other factors, including lack of family support, 
may also deter a woman from seeking medical 
help immediately.55 Thus, to reduce the TNBC 
burden in Nigeria, there is a critical unmet need 
to develop a more nuanced understanding of the 
wider social context of the human lives it affects 
and develop focused interventions to address all 
exacerbating factors.
Other Potential Risk Factors
Infectious agents or environmental estrogens 
such as insecticides and dichlorodiphenyltri-
chloroethane, used for preventing insect-borne 
diseases like malaria, are postulated to elevate 
risk for developing hormonal-related diseases, 
because they can alter hormone levels.43 Cos-
metic products frequently used among African 
women, such as hair relaxers and skin lighten-
ers, may also be contributing to increased risk 
for TNBC among Nigerian women, because 
these contain dangerous carcinogens and/or 
hormonally active compounds.43 Their potential 
influence on TNBC risk in Nigeria merits further 
study.
ADDING FUEL TO THE FIRE: CHALLENGES IN TNBC 
CARE AND TREATMENT IN NIGERIA
“Access to healthcare shouldn’t depend on your 
postcode.” —Richard Di Natale
The resource-constrained Nigerian health care 
system, lack of education and empowerment, 
poverty, shortage of well-trained health care per-
sonnel, and inadequate research infrastructure, 
as compared with other countries in the world 
such as the United States, have had significant 
adverse impacts on TNBC outcomes among the 
Nigerian population.
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Table 3. Comparison of BC Biomarker Status Between Lymph Node–Matched Patients 
With BC in Nigeria and the United Kingdom (Continued)
Biomarker
No. (%)
P*
United 
Kingdom† Nigeria‡
p53 < .001
Negative 222 (72.1) 80 (26.0)
Positive 81 (26.3) 138 (44.8)
HER2 .08
Negative 265 (86.9) 208 (81.6)
Positive 40 (13.1) 47 (18.4)
Triple negative < .001
No 218 (78.1) 108 (53.5)
Yes 61 (21.9) 94 (46.5)
Molecular classification < .001
Luminal A 211 (70.3) 48 (26.1)
Luminal B 17 (5.7) 10 (5.4)
Basal 30 (10.0) 69 (37.5)
HER2 23 (7.7) 34 (18.5)
Abbreviations: BC, breast cancer; EGFR, epidermal growth factor receptor; ER, estrogen receptor; 
HER2, human epidermal growth factor receptor 2; PR, progesterone receptor. 
*P values were calculated using the χ2 test.
†British cohort: 308 formalin-fixed, paraffin-embedded (FFPE) specimens from patients with BC 
presenting between 1986 and 1993 from the Nottingham-Tenovus Primary Breast Carcinoma 
Series.
‡Nigerian cohort: 308 FFPE specimens from patients with BC presenting from January 2002 to 
December 2008 at Olabisi University Teaching Hospital in Sagamu and Histopathology Specialist 
Laboratory Hospital in Idi-Araba, Lagos, Nigeria.
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Inadequate Health Care Infrastructure
A study conducted in a Nigerian teaching hos-
pital in southwestern Nigeria found that the 
average duration between onset of BC symp-
toms and presentation was approximately 11.2 
months, and approximately 39% of women pre-
sented with fungating tumors.43 In addition to 
aforementioned cultural and awareness-related 
factors, the delay in seeking medical attention 
may also be attributed to prohibitive cost of 
treatment, lack of transportation or access to 
radiology and chemotherapy facilities, and hos-
pital overcrowding.56-60 In Nigeria, out-of-pocket 
expenditure for health care was an alarming 
95.7% in 2014 according to the WHO. WHO 
reported that Nigeria allocates only $67 per per-
son for health care, and financial constraints 
were the primary reason for patients with BC 
discontinuing treatments. Quality of health care 
also leaves much to be desired, and inappro-
priate surgeries and biopsy management lead 
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Fig 2. Overall survival comparison between patients with breast cancer (BC) in Nigeria and the United Kingdom. Overall survival of 
lymph node–matched patients with BC in Nigeria (n = 308) and the United Kingdom (n = 308) observed at Olabisi University Teaching 
Hospital in Sagamu, Nigeria, and the Nottingham-Tenuous Primary Breast Carcinoma Series, respectively, among (A) estrogen receptor 
(ER) –positive, (B) ER-negative, and (C) all cases. (D) Overall survival among Nigerian patients with ER-negative and ER-positive disease. 
Nigerian patients presented between January 2002 and December 2008, and UK patients presented between 1986 and 1993.
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to late-stage presentation.61 Palliative care is 
often the only option for patients diagnosed in 
advanced stages; however, pain medications are 
often limited or unavailable, especially in rural 
areas.62
Inferior health care infrastructure, especially 
paucity of facilities for BC detection and treat-
ment, majorly underlies late presentation and 
poor clinical outcomes among Nigerian patients 
with TNBC. Nigeria is one of the least developed 
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countries with regard to oncology services, 
resources, and radiation therapy facilities.9 
Nigeria houses seven radiotherapy laboratories; 
however, only 15% of the reported 4 million 
Nigerians needing radiotherapy have access to 
these facilities.63,64 Furthermore, lack of trained 
personnel to properly operate radiotherapy 
equipment results in poor maintenance and 
equipment malfunction.9 The majority of the 
radiology equipment at cancer treatment centers 
is considered nonfunctional because of a lack 
of qualified personnel who can properly handle 
the equipment.65 The frequent breakdown of 
radiotherapy equipment may be attributed to 
equipment procurement without consultation or 
advice from end users, unreliable electricity, high 
cost of operation, bottlenecks in securing spare 
parts, absence of maintenance contracts with 
suppliers, and lack of quick response from for-
eign engineers when equipment malfunctions.9 
In addition, mammography facilities are scarce 
in Africa, and they inadequately detect cancer 
in women with dense breasts.66 Mammography 
screening may not detect all tumors in women 
at the premenopausal age, when the bulkiness 
of the breast is often an interference in Nigerian 
women.11,67 Furthermore, public hospitals are 
often overcrowded, lack human resources, and 
require long waiting periods, which stalls screen-
ing, diagnosis, and treatment of patients.68 Also, 
lack of follow-up and poor patient recordkeeping 
in clinics interfere with determination of specific 
factors influencing survival patterns for refine-
ment of treatment plans.39
Pathology practices. Subpar pathology prac-
tices are prevalent in many centers in Nigeria 
and often result in inaccurate diagnoses and 
consequently inappropriate treatment. Incorrect 
immunohistochemistry results attributable to 
poor tissue collection or processing, delayed fix-
ation or overfixation, poor-quality reagents, incor-
rect laboratory techniques, and lack of quality 
assurance practices are often prime suspects. 
Records about cause of death are often not noti-
fiable or centrally maintained. Although Nigeria 
is one of the few African countries that have pub-
lished guidelines, created by the Nigeria Breast 
Pathology Working Group in 2010, on standard-
ized pathology reporting, these guidelines have 
not been adequately circulated or implemented 
in medical centers. Daramola et al69 compared 
histologic parameters in pathology reports from 
a teaching hospital in Nigeria with the cancer 
data set of the Royal College of Pathologists in 
the United Kingdom to verify compliance and 
concordance. Almost half of the Nigerian BC 
cases examined were discordant with the Royal 
College of Pathologists, and roughly half of the 
cases were either undergraded or overgraded. 
Poor fixation and exclusion of mitotic count were 
underlying factors for discordant grading. Thus, 
proper training and education of Nigerian pathol-
ogists are critical to improving accuracy in BC 
diagnosis and reporting. Templates or proformas 
have been suggested for use by African patholo-
gists to guide accurate reporting.
Lack of health care personnel. The severe short-
age of competent health care providers, includ-
ing oncologists, radiologists, surgeons, and 
pathologists, has also contributed to the poor 
BC-related outcomes in Nigeria. The number 
of physicians per 100,000 people in Africa is 
presently 12, which is much lower than the 387 
physicians per 100,000 people in Europe.70,71 
The number of physicians per 100,000 people 
in Nigeria is currently 18.8, which is much lower 
than the numbers per 100,000 people in most 
Western nations, including the United States, 
where there are approximately 148 physicians 
per 100,000 people.71,72 Nigeria currently ranks 
seventh highest among 57 countries in the world 
facing a health care shortage crisis, according to 
the Federal Ministry of Health. Adebayo et al72 
reported that there are 33.% and 29.3% gaps in 
the supply of doctors and nurses, respectively, in 
Nigeria.72 The shortage of pathologists in Nige-
ria is also extreme, with only 6% of practicing 
specialist physicians certified as pathologists.73 
Furthermore, Nigeria possesses fewer than 40 
trained radiation oncologists to provide radiology 
services and meet the needs of the growing pop-
ulation of patients with cancer.65 The paucity of 
practicing clinicians in African countries can be 
attributed to a significant reduction (6% to 18%) 
in medical school teaching staff, who have opted 
to emigrate over the past 5 years (phenomenon 
known as brain drain).73,74 Many trainees often 
leave countries in sub-Saharan Africa for devel-
oping countries because of inadequate infra-
structure to practice, poor working conditions, 
and low remuneration.73 Implementing strat-
egies to attract more African health care per-
sonnel, such as raising salaries and improving 
working conditions, will be crucial to ensuring 
adequate patient coverage. Fortunately, Nigeria 
possesses a number of highly skilled, motivated, 
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and overseas-trained clinicians who can serve 
as conduits for revamping health care and con-
quering challenges of TNBC management.
Research
Research provides the evidence base on which 
cancer prevention, control, and treatment strate-
gies are built. The numbers of cancer research-
ers, including epidemiologists, statisticians, 
scientists, public health experts, health econ-
omists, and behavioral scientists, in Africa are 
limited. Although Nigeria is among the top coun-
tries in Africa for publishing research articles 
on BC, cutting-edge research is still lacking.75 
There is also a significant shortage of cancer 
registries and trained cancer registry personnel. 
In 2006, only 11% of the African population was 
covered by a cancer registry.76 Nigeria has many 
population-based cancer registries, such as the 
Ibadan Cancer Registry located in South West 
Nigeria and the Abuja Cancer Registry located in 
North Central Nigeria.77 Both ensure high-quality 
cancer data; however, together they cover only 
2.5% of the Nigerian population. In addition, the 
scarcity of data on cancer statistics and trends 
may be a result of government prioritization of 
funding of research on communicable diseases, 
rather than cancer research, infrastructure, or 
treatment. Furthermore, cancer advocates and 
trained community health care workers respon-
sible for educating the public and policymakers 
on cancer are unable to meet the needs of the 
nation.
TAKING MATTERS INTO OUR OWN HANDS: THE 
INTERNATIONAL CONSORTIUM FOR ADVANCING 
RESEARCH ON TNBC
“United we conquer, divided we fall.” —Aesop
The increased global awareness of the alarming 
worldwide BC burden has sparked the launch 
of several global and local initiatives targeting 
BC and TNBC globally and in Nigeria (Appendix 
Table A1). However, global initiatives centered 
on alleviating the TNBC burden in Nigeria and 
around the world are almost nonexistent. In 
view of this unmet need to improve outcomes 
for patients with TNBC by invigorating multidis-
ciplinary research on the fundamental biology of 
TNBC in diverse populations, our group, along 
with a leading BC research group led by Emad 
Rakha, MD, from Nottingham City Hospital 
(Nottingham, United Kingdom), jointly founded 
the International Consortium for Advancing 
Research on TNBC (ICART), a global coalition 
of TNBC researchers from the United States, 
Europe, Asia, and Africa. The mission of ICART is 
to consolidate, streamline, and share resources 
and mobilize and synergize complementary 
strengths to conduct large-scale multi-institu-
tional and high-impact clinical, translational, 
and population-based research projects related 
to TNBC (Fig 1). ICART includes a network of 14 
teaching hospitals across the length and breadth 
of Nigeria, and ICART researchers have already 
uncovered previously unrecognized disparities 
in breast clinicopathologic variables (Table 2), 
biomarker expression (Table 3), and survival 
(Fig 2) between lymph node–matched Nige-
rian and UK patients with BC that may underlie 
the stark disparity in clinical outcomes between 
these populations. ICART aims to leverage its 
network of highly skilled and well-qualified Nige-
rian clinicians and researchers to place Nigeria 
on the map for excellence in scientific research 
and health policy among low- to middle-income 
countries
CHALLENGES OF TNBC: OPPORTUNITIES FOR 
GROWTH
This review spotlights TNBC in Nigeria, where 
the disease has reached crisis levels. Insights 
generated from underlying drivers of this high 
prevalence would affect our understanding of 
the etiology and biology of TNBC globally; guide 
research to improve clinical management of 
TNBC, especially in women of African ancestry; 
and help design evidence-based, patient-cen-
tered, holistic, and efficacious policy frameworks 
and health awareness programs that factor in 
resource constraints while targeting key risk fac-
tors and cultural issues that may be exacerbating 
the burden of TNBC in certain nations or ethnic 
groups. The stark gap in adequate cancer care 
between Nigeria and the United States and strat-
egies to reduce this gap are shown in Figure 3. 
The challenges presented by TNBC worldwide 
and racial disparity in the United States require 
multilevel solutions and interventions, because 
the upstream determinants of outcomes span 
multiple domains of influence that are complexly 
intertwined. True impact will require targeted 
global initiatives like ICART, robust partner-
ships among governments and implementing 
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agencies, judicious resource allocation, politi-
cal will, incentives to promote innovation, team 
science, and focus on grassroots measures that 
have both the required reach and efficacy.
“Success is a staircase, not a doorway.” —Dottie 
Walters
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Appendix
Table A1. Initiatives That Aid in Reducing Burden of TNBC in Nigeria
Agency Level Initiative Type Objective or Action Potential Effect in Nigeria
International Atomic Energy 
Agency
Global Governmental Increase the number 
of effective and safe 
radiotherapy treatment 
centers available in 
developing African 
countries
Increased access to radiotherapy 
for patients with BC or TNBC
International Academy of 
Pathologists
Global Health care Educational exchanges on 
scientific, technologic, and 
methodologic advances in 
pathology practices
Improvement in quality and 
knowledge of proper pathology 
practices; more accurate 
diagnoses and patient record 
keeping/follow-up
African Organization for 
Research and Training
Continental Research Established the Cancer Plan 
for the African Continent 
(2013-2017) to revamp 
policy and funding 
for cancer research, 
increase public awareness 
and knowledge of the 
cancer burden in Africa, 
advance clinical oncology 
infrastructure and cancer 
health systems, and 
improve cancer prevention 
and control efforts
Development and improvement 
of regional infrastructure to 
support basic and translational 
BC and TNBC research (into 
areas like surveillance, genetic 
testing, decision making, 
propagation of evidence for 
intervention, epidemiology, 
and measurement)
International Agency on Cancer 
Research
Global Research Promote the development 
of cancer registries in 
multiple countries across 
Africa
Improved reporting of BC and 
TNBC trends and patterns
Breast Health Global Initiative Global Health care Revamp health care 
infrastructure and increase 
education and awareness 
of early detection methods 
and risk factors
Earlier detection of BC and 
TNBC for timely intervention; 
improved facilities and 
treatment
Susan G. Komen for the Cure Global and national NGO Fund international community 
education and outreach 
programs; founded the 
TNBC Foundation
Increased awareness and 
knowledge of signs and 
symptoms and risk factors for 
BC and TNBC
TNBC Foundation Global NGO Increase awareness of TNBC 
and support the discovery 
of novel treatments for 
TNBC
Inspire establishment of more 
TNBC-focused initiatives 
globally; increase awareness 
of TNBC and dissemination 
of TNBC statistics and trends; 
advocate to increase resource 
allocation for alleviating 
burden of TNBC
American Cancer Society Global and  
national
NGO Established international 
initiatives for cancer control 
and prevention
Reduce incidence and mortality 
rates for BC and TNBC
(Continued on following page)
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Table A1. Initiatives That Aid in Reducing Burden of TNBC in Nigeria (Continued)
Agency Level Initiative Type Objective or Action Potential Effect in Nigeria
WHO Global NGO Collaborate with Susan G. 
Komen for the Cure to 
sponsor lectures and 
events educating the 
public on BC and to 
provide a safe platform for 
women to have open dialog 
on the disease
Increased awareness and 
knowledge of signs, 
symptoms, and risk factors of 
BC and TNBC
International Information 
Service Group 
Global NGO Network of 50 organizations 
from 30 LMICs, including 
Nigeria; partnered with 
several other organizations 
to increase awareness 
of cancer prevention 
worldwide
Increased awareness and 
knowledge on signs, 
symptoms, and risk factors of 
BC and TNBC
Union for International Cancer 
Control 
Global NGO Advocate for worldwide 
cancer initiatives by 
encouraging the inclusion 
of cancer in the global 
health agenda and 
development of global 
cancer burden initiatives 
and programs
Increase funding for BC and 
TNBC research and health 
care infrastructure
Nigerian Health Insurance 
Scheme by Decree 35 of 
1999 
National Governmental Limit the rise in health care 
costs, ensure health equity 
among Nigerian citizens, 
harness private sector 
cooperation for provision 
of health care services, 
and promote adequate 
distribution of health care 
facilities across the country
Increase health care coverage for 
Nigerian citizens
Nigerian Sovereign Investment 
Authority
National Governmental Establish specialized health 
care and diagnostic 
facilities, allocate more 
public funds to health 
care, facilitate cooperation 
between private and 
federal health care 
institutions, and improve 
health care access by 
boosting the number of 
primary health care centers
Modernize and expand health 
care services throughout 
the private sector; increase 
availability of specialized and 
advanced health care services
Nigerian Cancer Society National NGO Support development of 
cancer treatment and 
diagnostic facilities, public 
education on cancer, and 
cancer research
Increase BC awareness and 
discovery of novel treatments
Cancer Organization Public 
Enlightenment 
National NGO Support BC awareness; 
provide screening and 
counseling services
Increased knowledge of signs, 
symptoms, and risk factors 
of BC and TNBC and early 
detection and intervention
(Continued on following page)
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Table A1. Initiatives That Aid in Reducing Burden of TNBC in Nigeria (Continued)
Agency Level Initiative Type Objective or Action Potential Effect in Nigeria
Breast Cancer Association of 
Nigeria
National NGO Increase BC awareness, 
education, advocacy, and 
research; established 
Breast Cancer Awareness 
Outreach, which 
encourages women to 
practice BSE
Increased awareness and 
knowledge of signs, 
symptoms, and risk factors 
of BC and TNBC for early 
detection and timely 
intervention
Mama Cancer Foundation of 
Nigeria
National NGO Raise funds for cancer 
prevention, diagnosis, 
treatment, research, and 
support for patients with 
cancer and their families
Increase funding for health 
care facilities, BC and TNBC 
research infrastructure and 
preventative, diagnostic, 
and treatment methods and 
resources
Children Living with Cancer 
Foundation
National NGO Tend to Nigerian children with 
cancer
Reduce suffering of pediatric 
patients with BC or TNBC
Preventative Healthcare 
Initiative
National NGO Equip Nigerian women with 
knowledge, skills, and 
preventative strategies 
regarding BC to empower 
them to become proactive 
about their own health
Increased awareness of 
signs, symptoms, and risk 
factors or BC and TNBC for 
early detection and timely 
intervention
Society of Cancer Oncology and 
Research in Nigeria
National NGO Facilitate cancer research 
and training; secure 
professional development 
opportunities for Nigerian 
health care providers
Improve quality of BC and TNBC 
research and health care
Research Institute 
Establishment Act of 1977
National Governmental Established Nigerian Institute 
of Medical Research in 
Yaba, Lagos, Nigeria, to 
focus on health concerns 
in Nigeria
Improve clinical management of 
BC and TNBC
National Institute for 
Pharmaceutical Research 
and Development
National Government Advance pharmaceutical 
research and development
Increased development and 
commercialization of raw 
pharmaceutical materials; 
better access to medications 
for patients with BC and 
TNBC
Breast Cancer Clinic Initiative Local (at Lagos 
University 
Teaching 
Hospital in 
Lagos, Nigeria)
Health care Eliminate prolonged waiting 
times before therapy and 
improve channeling of 
patients into specialized 
treatment facilities 
to provide quick and 
optimum patient care
Minimize delays in BC treatment, 
which can help increase 
survival rates
Every Drop Counts initiative Local (at Ahmadu 
Bello University 
Teaching 
Hospital in Zaria, 
Nigeria)
Health care Establish an outpatient 
pharmacy unit in the 
oncology department to 
facilitate easier access 
for patients with cancer 
to obtain their prescribed 
medications
Reduced waiting times for 
receiving medication and 
reduced drug costs; improved 
dose precision; reduced 
contamination of medications
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Table A1. Initiatives That Aid in Reducing Burden of TNBC in Nigeria (Continued)
Agency Level Initiative Type Objective or Action Potential Effect in Nigeria
Educational workshop with 
pathologists and laboratory 
scientists from United 
Kingdom
Local (at National 
Hospital Abuja in 
Abuja, Nigeria)
Health care Help improve pathology 
practices, enhance 
knowledge of IHC, and 
enable progression to 
automated IHC in the 
hospital
Increased accuracy in BC 
and TNBC diagnosis and 
screening for prognostic 
biomarkers
Cancer Registry Project Local (University of 
Benin Teaching 
Hospital in 
Benin, Nigeria)
Health care Establish a hospital-based 
registry to curate cancer 
incidence and prevalence 
data
Provide more accurate data 
pertaining to BC and TNBC 
burden
Abbreviations: BC, breast cancer; BSE, breast self-examination; IHC, immunohistochemistry; LMIC, low- or middle-income country; NGO, nongovernmental organiza-
tion; TNBC, triple-negative breast cancer. 
Downloaded from ascopubs.org by UNIVERSITY NOTTINGHAM on August 28, 2018 from 128.243.039.098
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
